Testing blinatumomab with or without revumenib for KMT2A leukemia
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This study tests a combination of two medicines, blinatumomab and revumenib, for people with a specific genetic form of leukemia (KMT2A). The goal is to see if adding revumenib helps the treatment work better and keeps the cancer in remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of leukemia (ALL or ALAL) with a specific gene change called KMT2A translocation.
- You must be in your first complete remission after initial treatment (Cohort A) or be newly diagnosed (Cohort B).
- Your cancer must show a protein called CD19 on the leukemia cells.
- You must not have received certain prior treatments like blinatumomab, CAR-T, or menin inhibitors (for Cohort A).
- You must not have had a stem cell transplant before.
- You must have adequate kidney, liver, and heart function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests revumenib, a targeted medicine, to treat acute leukemia that has come back or hasn’t fully gone away. It may help people whose leukemia has specific gene changes (like KMT2A or NPM1) by trying to better control the cancer.
This Phase 2 study tests a combination of medicines (inotuzumab ozogamicin and blinatumomab), with or without ponatinib, for people with CD22-positive B-cell acute lymphoblastic leukemia (ALL). It aims to improve remission and control leukemia cells, including in the bone marrow.
This trial tests if adding a targeted drug (dasatinib or imatinib) to a chemotherapy combination with blinatumomab works better for children and young adults with a specific genetic form of B-cell acute lymphoblastic leukemia. The goal is to see if this approach can improve treatment outcomes for patients with Philadelphia chromosome-positive or ABL-class Ph-like B-ALL.
This trial tests a combination of three drugs (revumenib, azacitidine, and venetoclax) for children and young adults with a hard-to-treat type of leukemia that has a specific genetic change. The goal is to see if this new mix can help when standard treatments have not worked.
This trial tests two drugs (blinatumomab and revumenib) given together for people with a type of acute lymphoblastic leukemia (ALL) that has a specific genetic change called KMT2A. The combination aims to kill leukemia cells and may be an option for people whose leukemia has returned or not improved, or for older or less fit adults newly diagnosed.
This Phase 2 trial tests a combination of medicines to treat Philadelphia chromosome–positive (Ph-positive) or BCR-ABL–positive acute lymphoblastic leukemia (ALL), including cases that have come back or did not respond. It may help by targeting specific leukemia signals while also aiming to improve disease control.
Hear when a new Acute Leukemia of Ambiguous Lineage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.